Bone turnover and 1,25-dihydroxycholecalciferol during treatment with phosphate binders
نویسندگان
چکیده
منابع مشابه
Bone turnover during high dose inhaled corticosteroid treatment.
This study was performed to determine the effects of high doses of two inhaled corticosteroids, beclomethasone dipropionate and budesonide, on biochemical indices of bone turnover (urinary hydroxyproline:creatine and calcium:creatinine ratios, plasma alkaline phosphatase, and parathyroid hormone). Twelve healthy male doctors, aged 25-36 (mean 30) years, were studied. After a week's run in perio...
متن کاملBone and collagen turnover during treatment with inhaled dry powder budesonide and beclomethasone dipropionate.
OBJECTIVES To assess bone and collagen turnover in asthmatic children treated with dry powder budesonide from the Turbuhaler and dry powder beclomethasone dipropionate from the Diskhaler in a dose of 800 micrograms/day. SUBJECTS Thirteen prepubertal children with asthma. DESIGN Open crossover study with two treatment periods and treatment free run-in and wash-out periods. All periods were o...
متن کاملPhosphate binders and timing of levothyroxine administration.
1. Simeone DM, Sandelin K, Thompson NW. Undescended superior parathyroid gland: a potential cause of failed cervical exploration for hyperparathyroidism. Surgery 1995; 118: 949–956 2. Manley NR, Selleri L, Brendolan A et al. Abnormalities of caudal pharyngeal pouch development in Pbx1 knockout mice mimic loss of Hox3 paralogs. Dev Biol 2004; 276: 301–312 3. Billingsley KG, Douglas LF, Doppman J...
متن کاملOral phosphate binders: history and prospects.
The use of an oral phosphate binder is a promising and most practical strategy for the prevention of vascular calcification in patients with chronic kidney disease (CKD). To secure the safety: 1) the oral phosphate binder must not cause adverse effects in the gastrointestinal tract; 2) the oral phosphate binder should be non-absorbable or barely absorbable through the gastrointestinal tract, or...
متن کاملIron-based phosphate binders: do they offer advantages over currently available phosphate binders?
Increased cardiovascular morbidity and mortality has been associated with the hyperphosphatemia seen in patients with end-stage chronic kidney disease (CKD). Oral phosphate binders are prescribed in these patients to prevent intestinal absorption of dietary phosphate and reduce serum phosphate. In prospective observational cohorts they have shown to decrease all-cause and cardiovascular mortali...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Kidney International
سال: 1988
ISSN: 0085-2538
DOI: 10.1038/ki.1988.98